Arrowhead Pharmaceuticals Unveils Key Data on Hypertriglyceridemia…

Event summary

Arrowhead Pharmaceuticals will present new clinical data at the European Society of Cardiology Congress (ESC) in Munich on August 30 and 31, 2026.
Key presentations include 12-month results from the SHASTA-3 and SHASTA-4 pivotal trials for plozasiran in severe hypertriglyceridemia.
Arrowhead will also present data on a phase 3 trial of zodasiran for homozygous familial hypercholesterolemia (HoFH).
An investor webcast will be held on August 31, 2026, to review the trial results and include Q&A with key presenters.

The big picture

Arrowhead Pharmaceuticals is positioning itself as a leader in RNA interference (RNAi) therapeutics with a focus on intractable lipid disorders. The upcoming data presentations at ESC 2026 are critical for validating the company's pipeline and expanding its commercial footprint in severe hypertriglyceridemia and familial hypercholesterolemia. The strategic partnerships with Sanofi and regulatory designations underscore the potential for significant market impact.

What we're watching

Clinical Efficacy: How the 12-month results from the SHASTA-3 and SHASTA-4 trials will impact the regulatory and commercial prospects of plozasiran in severe hypertriglyceridemia.
Market Expansion: Whether the phase 3 trial data for zodasiran in HoFH will position Arrowhead for potential approvals and partnerships in the ultra-rare disease space.
Competitive Positioning: The pace at which Arrowhead can leverage its RNAi platform to maintain a leading edge in lipid-lowering therapies amid increasing competition.